Latest Nutraceuticals News

Decidr AI Industries delivered 99% revenue growth and a A$13.6 million annualised exit rate in FY26, but the company’s A$32.4 million loss and auditor-highlighted going concern uncertainty put funding at the centre of its next chapter. Management is targeting A$5 million in annualised savings while seeking to convert early AI deployments into recurring revenue.

Ocean Sciences delivered a sharp increase in seaweed revenue during FY2026, but the audited report also records a A$1.612 million continuing-operations loss, A$2.319 million operating cash outflow and material uncertainty over its ability to continue as a going concern. The renamed ASX-listed group is now seeking up to A$3 million while building out its Indonesian platform.

Clover Corporation has delivered record FY26 revenue of $97.4 million and a 50% lift in attributable profit, while raising its fully franked final dividend to 1.25 cents per share. The result comes alongside a planned chair transition, with Ian Glasson set to replace retiring chair Rupert Harrington after the 2026 AGM.

Xenitra Limited’s OPAL Real World Asset tokenised sales ecosystem has accelerated rapidly, crossing $1.1 million in product sales and onboarding over 400 distribution partners within seven weeks, signalling strong traction in Greater China.

BPH Global Ltd (ASX: BP8) posted its second best monthly seaweed trading result with gross sales of approximately A$391,000 in the twelfth month, pushing aggregate sales beyond A$3.3 million as Indonesian operations scale up post-monsoon.

BPH Global inks binding deal with Temasek Innovation Holdings to validate its seaweed-based male vitality product through targeted biological assays, advancing regulatory and commercial ambitions.

BPH Global’s Indonesian unit has locked in a four-year MoU with ITBM to integrate student-driven operations and research at its Takalar coastal seaweed site, setting the stage for scaled commercial development and local collaboration.

Holista Colltech has partnered with Swang Chai Chuan to develop a nano-collagen production facility in Western Australia, marking a major step in commercialising its collagen technology with a $1.6 million initial investment.

BPH Global’s Indonesian arm has entered Stage 2 of its collaboration with Indonesia’s National Research and Innovation Agency to develop fucoidan extraction technology and a powdered supplement prototype, targeting commercialisation within months.

BPH Global has secured a key coastal site in South Sulawesi to boost its seaweed cultivation and processing capabilities, underpinning its vertical integration strategy across food and bio stimulant markets.

Xenitra Limited’s Q3 sales soared to $8.3 million, a 300% jump over Q2, driven by its Nutritionals division and a strategic $30 million partnership with Rockcheck Group for Danone products. The company also launched new OTC medicines and blockchain tokenised sales channels poised to fuel future growth.

Xenitra Limited has acquired Hong Kong Fukang Trading Co., including key pharmaceutical licenses and ecommerce assets, to fully operationalise its OTC medicine business in Hong Kong and China.